Sandoz to pay $275 million to settle drug price-fixing case

Reuters
02-19
Sandoz to pay $275 million to settle drug price-fixing case

By Mike Scarcella

Feb 18 (Reuters) - Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who accused the company of conspiring with industry rivals to illegally fix prices.

Attorneys for the plaintiffs, including the City of Providence, Rhode Island and a New York City police employee benefits plan, asked U.S. District Judge Cynthia Rufe in Philadelphia on Friday to approve the settlement.

Sandoz denied any wrongdoing in agreeing to settle. The company said it will cooperate with the plaintiffs as they pursue claims against other drugmakers.

The antitrust case includes several drug makers that were not part of Friday's settlement, including Pfizer, Teva and Lupin. The companies did not immediately respond to requests for comment and have denied wrongdoing.

Sandoz and attorneys for the plaintiffs, "end-purchasers" including consumers who bought Sandoz drugs from pharmacies, did not immediately respond to requests for comment.

The settlement period covers some purchases between 2009 and 2019 for drugs, including the antidepressants amitriptyline and clomipramine, and for clobetasol, which is used to treat some skin conditions.

The settlement class likely includes millions of members with claims tied to Sandoz’s alleged price-fixing, the plaintiffs' lawyers told the court.

Their court filing said “continued litigation of the claims against Sandoz would be protracted and without guarantee of any recovery.”

The attorneys said they will seek up to $91.6 million in legal fees and $26 million in litigation expenses.

Sandoz last year agreed to pay $265 million to resolve related claims lodged in the litigation by a group of wholesale drug purchasers and others.

The case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, U.S. District Court for the Eastern District of Pennsylvania, No. 2:16-MD-02724.

For end-payor class: Roberta Liebenberg and Jeffrey Istvan of Fine, Kaplan and Black

For Sandoz: Matthew Kent of Alston & Bird

Read more:

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims

Ex-Sandoz exec gets probation for price-fixing after cooperation deal

US drops price-fixing case against former Taro Pharmaceutical executive

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10